R I Haddad1, E Massarelli2, J J Lee3, H Y Lin3, K Hutcheson4, J Lewis5, A S Garden6, G R Blumenschein5, W N William7, R R Pharaon8, R B Tishler9, B S Glisson5, C Pickering4, K A Gold10, F M Johnson5, G Rabinowits11, L E Ginsberg12, M D Williams13, J Myers4, M S Kies5, V Papadimitrakopoulou14. 1. Department of Medical Oncology, Dana Farber Cancer Institute, Boston. 2. Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston; Department of Medical Oncology and Therapeutics Research, City of Hope Cancer Center, Duarte. 3. Departments of Biostatistics. 4. Head and Neck Surgery. 5. Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston. 6. Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, USA. 7. Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston; Oncology Center, Hospital BP, A Beneficencia Portuguesa de São Paulo, São Paulo, Brazil. 8. Department of Medical Oncology and Therapeutics Research, City of Hope Cancer Center, Duarte. 9. Department of Radiation Oncology, Dana Farber Cancer Institute, Boston. 10. Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston; Division of Hematology and Oncology, University of California San Diego Moores Cancer Center, La Jolla. 11. Department of Medical Oncology, Dana Farber Cancer Institute, Boston; Department of Head and Neck Oncology, Baptist Health South Florida, Coral Gables. 12. Departments of Diagnostic Radiology. 13. Pathology, University of Texas MD Anderson Cancer Center, Houston, USA. 14. Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston. Electronic address: vpapadim@mdanderson.org.
Abstract
BACKGROUND: The survival advantage of induction chemotherapy (IC) followed by locoregional treatment is controversial in locally advanced head and neck squamous cell carcinoma (LAHNSCC). We previously showed feasibility and safety of cetuximab-based IC (paclitaxel/carboplatin/cetuximab-PCC, and docetaxel/cisplatin/5-fluorouracil/cetuximab-C-TPF) followed by local therapy in LAHNSCC. The primary end point of this phase II clinical trial with randomization to PCC and C-TPF followed by combined local therapy in patients with LAHNSCC stratified by human papillomavirus (HPV) status and T-stage was2-year progression-free survival (PFS) compared with historical control. PATIENTS AND METHODS: Eligible patients were ≥18 years with squamous cell carcinoma of the oropharynx, oral cavity, nasopharynx, hypopharynx, or larynx with measurable stage IV (T0-4N2b-2c/3M0) and known HPV by p16 status. Stratification was by HPV and T-stage into one of the two risk groups: (i) low-risk: HPV-positive and T0-3 or HPV-negative and T0-2; (ii) intermediate/high-risk: HPV-positive and T4 or HPV-negative and T3-4. Patient reported outcomes were carried out. RESULTS:A total of 136 patients were randomized in the study, 68 to each arm. With a median follow up of 3.2 years, the 2-year PFS in the PCC arm was 89% in the overall, 96% in the low-risk and 67% in the intermediate/high-risk groups; in the C-TPF arm 2-year PFS was 88% in the overall, 88% in the low-risk and 89% in the intermediate/high-risk groups. CONCLUSION: The observed 2-year PFS of PCC in the low-risk group and of C-TPF in the intermediate/high-risk group showed a 20% improvement compared with the historical control derived from RTOG-0129, therefore reaching the primary end point of the trial.
RCT Entities:
BACKGROUND: The survival advantage of induction chemotherapy (IC) followed by locoregional treatment is controversial in locally advanced head and neck squamous cell carcinoma (LAHNSCC). We previously showed feasibility and safety of cetuximab-based IC (paclitaxel/carboplatin/cetuximab-PCC, and docetaxel/cisplatin/5-fluorouracil/cetuximab-C-TPF) followed by local therapy in LAHNSCC. The primary end point of this phase II clinical trial with randomization to PCC and C-TPF followed by combined local therapy in patients with LAHNSCC stratified by human papillomavirus (HPV) status and T-stage was 2-year progression-free survival (PFS) compared with historical control. PATIENTS AND METHODS: Eligible patients were ≥18 years with squamous cell carcinoma of the oropharynx, oral cavity, nasopharynx, hypopharynx, or larynx with measurable stage IV (T0-4N2b-2c/3M0) and known HPV by p16 status. Stratification was by HPV and T-stage into one of the two risk groups: (i) low-risk: HPV-positive and T0-3 or HPV-negative and T0-2; (ii) intermediate/high-risk: HPV-positive and T4 or HPV-negative and T3-4. Patient reported outcomes were carried out. RESULTS: A total of 136 patients were randomized in the study, 68 to each arm. With a median follow up of 3.2 years, the 2-year PFS in the PCC arm was 89% in the overall, 96% in the low-risk and 67% in the intermediate/high-risk groups; in the C-TPF arm 2-year PFS was 88% in the overall, 88% in the low-risk and 89% in the intermediate/high-risk groups. CONCLUSION: The observed 2-year PFS of PCC in the low-risk group and of C-TPF in the intermediate/high-risk group showed a 20% improvement compared with the historical control derived from RTOG-0129, therefore reaching the primary end point of the trial.
Authors: Glaucia Maria de Mendonça Fernandes; Vilson Serafim Junior; Ana Lívia Silva Galbiatti-Dias; Leticia Antunes Muniz Ferreira; Márcia Maria Urbanin Castanhole-Nunes; Rosa Sayoko Kawasaki-Oyama; José Victor Maniglia; Erika Cristina Pavarino; Eny Maria Goloni-Bertollo Journal: Am J Cancer Res Date: 2022-09-15 Impact factor: 5.942
Authors: Hélène Carinato; Mickaël Burgy; Régine Ferry; Cathie Fischbach; Michal Kalish; Sébastien Guihard; Youssef Brahimi; Henri Flesch; Guy Bronner; Philippe Schultz; Véronique Frasie; Alicia Thiéry; Martin Demarchi; Thierry Petit; Alain C Jung; Pierre Wagner; Pierre Coliat; Christian Borel Journal: Front Oncol Date: 2021-10-27 Impact factor: 6.244
Authors: Dina Oksen; Patricia Prince; Emmanuelle Boutmy; Elizabeth M Garry; Barbara Ellers-Lenz; Adina Estrin; Andreas Johne; Patrice Verpillat; Nicolle M Gatto Journal: Clin Transl Sci Date: 2022-06-11 Impact factor: 4.438